For the year ending 2025-12-31, APGE had -$10,534K decrease in cash & cash equivalents over the period. -$232,597K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -255,843 |
| Depreciation expense | 1,418 |
| Equity-based compensation expense | 46,277 |
| Amortization of discounts on marketable securities | 7,501 |
| Non-cash lease expense | 3,677 |
| Prepaid expenses and other current assets | 2,106 |
| Other assets | 8,467 |
| Accounts payable | 150 |
| Operating lease liability | -3,981 |
| Accrued expenses | -1,074 |
| Net cash used in operating activities | -227,450 |
| Purchases of marketable securities | 642,300 |
| Maturities of marketable securities | 467,873 |
| Purchases of property and equipment | 5,147 |
| Net cash used in investing activities | -179,574 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | 324,052 |
| Proceeds from issuance of common stock under atm equity offering program, net of issuance costs | 65,582 |
| Proceeds from exercise of options and employee stock purchase plan purchases | 6,856 |
| Net cash provided by financing activities | 396,490 |
| (decrease) increase in cash, cash equivalents and restricted cash | -10,534 |
| Cash, cash equivalents and restricted cash, beginning of period | 142,083 |
| Cash, cash equivalents and restricted cash, end of period | 131,549 |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)